logo

INKT

MiNK Therapeutics·NASDAQ
--
--(--)
--
--(--)

INKT fundamentals

MiNK Therapeutics (INKT) released its earnings on Nov 14, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.65 (YoY -1200.00%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.65
-1200.00%
Report date
Nov 14, 2025
INKT Earnings Call Summary for Q3,2025
  • Clinical Milestone: agenT-797 achieves 23-month median OS in refractory solid tumors, exceeding historical benchmarks by 383%.
  • Strategic Expansion: $15.5M+ cash runway through 2026, supporting global Phase II/III pulmonary trial and GvHD study.
  • Manufacturing Strength: 1B cells/donor yield enables cost-efficient stockpiling, with 3-year shelf life for iNKT cells.
  • Partnership Power: Federal grants and academic collaborations reduce capital intensity by 70%+ for late-stage programs.
EPS
Revenue

Revenue & Expenses

Key Indicators

MiNK Therapeutics (INKT) key financial stats and ratios, covering profitability, financial health, and leverage.
MiNK Therapeutics (INKT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
MiNK Therapeutics (INKT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
MiNK Therapeutics (INKT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does MiNK Therapeutics (INKT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track MiNK Therapeutics (INKT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield